Study Says Combined Drugs Can Shrink Tumour By 60 Percent In Bowel Cancer

Updated Jul 25, 2024 | 06:09 PM IST

SummaryA new study has found that combining the use of botanciiimab and balstilumab can reduce tumours caused by bowel cancer by 60%, marking the first time a durable response to immunotherapy has been reported in patients suffering from this condition.
close-up-medicine-containers-table

A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

End of Article

FDA Recalls Popular Thyroid Medication: What Levothyroxine Users Need to Know

Updated Jul 27, 2026 | 08:00 AM IST

SummaryThe U.S. Food and Drug Administration (FDA) recently issued a Class-II recall of levothyroxine sodium tablets , a commonly prescribed thyroid medication.
FDA Recalls Popular Thyroid Medication: What Levothyroxine Users Need to Know

Credit: AI

Millions of people with hypothyroidism depend on levothyroxine every day to replace the thyroid hormone their body cannot produce.

Now, the U.S. Food and Drug Administration (FDA) has announced a nationwide recall of certain batches of levothyroxine sodium tablets after they were found to be subpotent, meaning they contain less active medication than stated on the label.

Experts caution that ingesting a lower-than-prescribed dose could allow hypothyroidism symptoms to return, particularly in vulnerable groups like pregnant women, infants, and people with thyroid cancer.

Why Did FDA Recall Levothyroxine?

The FDA has issued a Class II recall for specific lots of levothyroxine sodium tablets distributed by Major Pharmaceuticals. Testing found that the recalled tablets were below the approved potency specification, meaning they may not deliver the intended amount of thyroid hormone.

The recall affects multiple strengths packaged in 100-tablet cartons and 10-count blister packs. Dosages involved include 25 mcg, 50 mcg, 75 mcg, 88 mcg, 112 mcg, 125 mcg and 150 mcg.

The FDA has categorized the action as a Class II recall. According to the agency, a Class II recall means: "Use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."

This means the recall is important but does not come under FDA's highest-risk category.

Also read: Is Your Allergy Medicine Safe? FDA Recalls Antihistamine Tablets Over Life-Threatening Contamination Concerns

Why A Subpotent Thyroid Medicine A Concern?

Even relatively small differences in levothyroxine dose can affect how well the medicine works. If they contain less hormone than needed, patients may receive insufficient thyroid replacement. Possible consequences include:

  • Fatigue
  • Weight gain
  • Feeling unusually cold
  • Constipation
  • Depression or low mood
  • Brain fog
  • Dry skin
  • Slower heart rate

In some higher-risk individuals, inadequate thyroid hormone replacement could have more severe consequences, including worsening hypothyroidism or interference with thyroid cancer treatment.

Also read: CDC's 'Vaccines Do Not Cause Autism' Webpage Sparks Debate; Republican Senator Seeks Clarity

What Does This Recall Mean For Patients?

Because thyroid hormone influences nearly every organ system, taking the correct dose consistently is essential.

Also read: Montelukast Mental Health Warning Still Largely Overlooked By Psychiatrists

Do not stop taking levothyroxine on your own. Stopping thyroid medication suddenly can lead to worsening hypothyroidism and other complications. Instead, patients should:

  • Check whether their medication's lot number matches the recalled batches.
  • Contact your pharmacist or physician.
  • Obtain a replacement if their medication is affected.
  • Continue treatment unless instructed otherwise by a healthcare professional.

Other Recently Recalled Medications

The FDA also announced recently that it is recalling four lots of Cetirizine Hydrochloride Tablets USP 5 mg made by India-based company Unique Pharmaceutical Laboratories due to potential cross-contamination with ranitidine, a medication used to treat heartburn and stomach ulcers.

Although Unique Pharmaceutical Laboratories said it has not received any reports of adverse reactions related to the recalled tablets, the contamination could pose a serious risk for people who are allergic or hypersensitive to ranitidine.

The latest FDA recall serves as a reminder that quality control remains critical for medications taken every day. For anyone taking levothyroxine, experts recommend checking medication packaging against the FDA recall notice and speaking with a healthcare provider or pharmacist if there is any uncertainty.

End of Article

Florida Sees Rise In Leprosy Cases: Why Is The Ancient Disease Still Found In This State

Updated Jul 27, 2026 | 07:00 AM IST

SummaryFlorida still sees leprosy cases, a disease long eradicated, due to wild nine-banded armadillos found in the state. Currently, 17 cases of leprosy have been reported so far.
Florida Sees Rise In Leprosy Cases: Why Is The Ancient Disease Still Found In This State

Credit: AI

Florida is once again reporting an increase in Hansen's disease (leprosy) cases, renewing attention to a disease that got eradicated decades ago.

While the infection remains rare in the United States, health officials say Florida continues to report one of the country's highest numbers of locally acquired cases, with recent infections concentrated in several Central Florida counties.

According to the Florida Department of Health, 17 cases of leprosy had been reported statewide through mid-July 2026, with multiple cases identified in Brevard, Lake, Orange, Seminole, Sumter, and Volusia counties.

Local health experts say the disease is uncommon but not unexpected in Florida, where environmental and wildlife factors contribute to its persistence.

Why Does Leprosy Still Exist In Florida?

Also read: WHO Declares Australia Free Of Trachoma: All About The Irreversible Blindness

Unlike many parts of the world where leprosy is associated human-to-human transmission, Florida has a unique risk factor: wild nine-banded armadillos.

Research has shown that armadillos are natural reservoirs of Mycobacterium leprae, the bacterium that causes leprosy.

Humans may become infected after frequent contact with infected armadillos or contaminated soil where the bacteria may persist. Experts emphasize that not every armadillo carries the bacteria.

Scientists also believe Florida has become endemic for leprosy, meaning the disease is now established locally rather than being introduced through international travel.

Increasing numbers of patients have reported no history of foreign travel or known contact with someone diagnosed with leprosy, suggesting local transmission is still prevalent.

All About Leprosy

Also read: Chile Becomes The First Country In Americas To Eliminate Leprosy, Says WHO

Leprosy, also known as Hansen's disease, is a chronic bacterial infection caused primarily by Mycobacterium leprae. The disease mainly affects:

  • Skin
  • Peripheral nerves
  • Eyes
  • Upper respiratory tract lining

If diagnosed early, it is completely curable. Delayed treatment, however, can result in permanent nerve damage, muscle weakness, and disability.

How Does It Spread?

Contrary to longstanding myths, leprosy is not highly contagious. Health experts say the infection usually spreads through prolonged, close contact with untreated individuals, likely via respiratory droplets.

Casual interactions like shaking hands, hugging, sharing meals, or sitting next to someone do not typically spread the disease.

The illness also has an unusually long incubation period, often taking 2 to 20 years before symptoms appear, making it difficult to identify exactly where and when an infection occurred. Early symptoms may include:

  • Pale or reddish skin patches with reduced sensation
  • Numbness in the hands or feet
  • Tingling or nerve pain
  • Muscle weakness
  • Thickened peripheral nerves

Because symptoms develop gradually, many patients are diagnosed only after nerve damage has already begun.

Experts advise avoiding unnecessary handling of wild armadillos and seeking medical evaluation for persistent numb skin lesions, especially after possible exposure

Although leprosy is curable, its persistence in Florida highlights how infectious diseases can survive in animal reservoirs even after becoming rare in humans.

Public health experts say improving awareness among both doctors and the public is essential for early diagnosis, timely treatment, and preventing permanent disability.

End of Article

CDC's 'Vaccines Do Not Cause Autism' Webpage Sparks Debate; Republican Senator Seeks Clarity

Updated Jul 27, 2026 | 06:10 AM IST

SummaryCDC recently made changes to its autism and vaccine webpage, which sparked fresh debates. Republican Senator Bill Cassidy criticised the health body.
CDC's 'Vaccines Do Not Cause Autism' Webpage Sparks Debate; Republican Senator Seeks Clarity

Credit: AI

The U.S. Centers for Disease Control and Prevention's (CDC) revised webpage on autism and vaccines has reignited debate over how health agencies should communicate scientific evidence.

Republican Senator Bill Cassidy slammed the agency's messaging while continuing to defend the overwhelming scientific evidence that vaccines do not cause autism.

CDC Makes Changes To Its Autism And Vaccine Webpage

The controversy was sparked on changes made to the CDC's autism webpage, which now states that the claim "vaccines do not cause autism" is "not an evidence-based claim" as studies have not ruled out every possible link between infant vaccines and autism.

The page also says the U.S. Department of Health and Human Services (HHS) is continuing to investigate the causes of autism.

The revised language represents a shift from the CDC's longstanding public messaging, which for years stated that extensive scientific research had found no causal relationship between vaccines and autism.

The changes have drawn criticism from scientists, physicians, and lawmakers who fear they could weaken public confidence in routine childhood immunization.

Also read: US FDA Identifies New Cyclospora Outbreak As Michigan Cases Top 7,000: Why Is The Source So Hard To Trace?

Republican Senator Bill Cassidy Reacts

Sen. Bill Cassidy, a Louisiana Republican, physician, and chairman of the Senate Health, Education, Labor and Pensions Committee, recently said discussions with CDC Director nominee Dr. Erica Schwartz and HHS officials led to what he described as a "good faith" revision of the webpage.

"As a sign of good faith, HHS modified the CDC's autism and vaccines webpage. There is more to do to repair the damage that has been done to the U.S. public health response, but this is a start," Cassidy said.

Cassidy had previously questioned whether future CDC leadership would protect scientific integrity and resist political pressure on vaccine policy during Schwartz's Senate confirmation hearing.

While Cassidy ultimately announced his support for Schwartz's nomination, he has continued to stress that the agency should responsibly communicate established scientific evidence regarding vaccines.

Also read: Legionnaires' Disease Claims 5th Life In New York City: Health Officials

Scientific Consensus Remains Intact

Despite the debate surrounding the CDC webpage, the broader scientific consensus has not changed.

Large studies conducted over several decades in multiple countries have consistently found no evidence that routine childhood vaccines cause autism.

Major medical organizations continue to support vaccination as one of the safest and most effective public health interventions.

Health experts have also warned that ambiguous or conflicting public health messaging could further affect vaccine confidence at a time when the United States is experiencing its highest number of measles cases in more than three decades, largely driven by declining childhood vaccination rates.

The controversy highlights the growing tension between political oversight and scientific communication within U.S. public health agencies.

For public health experts, the concern extends beyond a single webpage. They argue that how government agencies present scientific evidence can directly influence vaccine confidence, healthcare decisions, and efforts to prevent outbreaks of vaccine-preventable diseases.

End of Article